First line therapy with Bendamustine in advanced indolent Non-Hodgkin Lymphoma in treatment routine – interim analysis of the non-interventional study Be-1st. 31. Mai 2011 Becker, M., Tschechne, B., Reeb, M., Schwinger, U., Grass, J., Straßl, L., 2011. Onkologie 34 (suppl.6)(P891), 268. doi:10.1159/000333305 Abstract Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial. Bartlett, J.M.S., Brookes, C.L., Robson, T., van de Velde, C.J.H., Billingham, L.J., Campbell, F.M., Grant, M., Hasenburg, A., Hille, E.T.M., Kay, C., Kieback, D.G., Putter,… Weiterlesen REASON: A Registry for the Epidemiologic and Scientific evaluation of EGFR mutation status in newly diagnosed NSCLC patients stage IIIB/IV. Dietel, M., Schütte, W., Thomas, M., Eberhardt, W., Graf von der Schulenburg, J.-M., Schirmacher, P., 2011. Weiterlesen